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Abstract
Background: A recent study by Page et al. (PLoS Med. 2016;13(5):e1002028) claimed that increasing numbers of
reviews are being published and many are poorly-conducted and reported. The aim of the present study was to
assess how well reporting standards of systematic reviews produced in a Health Technology Assessment (HTA)
context compare with reporting in Cochrane and other ‘non-Cochrane’ systematic reviews from the same years
(2004 and 2014), as reported by Page et al. (PLoS Med. 2016;13(5):e1002028).
Methods: All relevant UK HTA programme systematic reviews published in 2004 and 2014 were identified. After
piloting of the form, two reviewers each extracted relevant data on conduct and reporting from these reviews.
These data were compared with data for Cochrane and “non-Cochrane” systematic reviews, as published by Page
et al. (PLoS Med. 2016;13(5):e1002028). All data were tabulated and summarized.
Results: There were 30 UK HTA programme systematic reviews and 300 other systematic reviews, including
Cochrane reviews (n = 45). The percentage of HTA reviews with required elements of conduct and reporting was
frequently very similar to Cochrane and much higher than all other systematic reviews, e.g. availability of protocols
(90, 98 and 16% respectively); the specification of study design criteria (100, 100, 79%); the reporting of outcomes
(100, 100, 78%), quality assessment (100, 100, 70%); the searching of trial registries for unpublished data (70, 62,
19%); reporting of reasons for excluding studies (91, 91 and 70%) and reporting of authors’ conflicts of interests
(100, 100, 87%). HTA reviews only compared less favourably with Cochrane and other reviews in assessments of
publication bias.
Conclusions: UK HTA systematic reviews are often produced within a specific policy-making context. This context
has implications for timelines, tools and resources. However, UK HTA systematic reviews still tend to present
standards of conduct and reporting equivalent to “gold standard” Cochrane reviews and superior to systematic
reviews more generally.
Keywords: Systematic review, Health technology assessment, HTA, Cochrane collaboration, Reporting, PRISMA
Background
Systematic reviews are seen as having an important role
in decision-making processes, especially in medicine and
health, and the numbers of published reviews are
increasing [1]. Under such circumstances, the issue of
the quality of these reviews is also becoming increasingly
important. A recent analysis of the epidemiology and
reporting characteristics of systematic reviews by Page
et al. [1] found that the quality of the conduct and
reporting of many reviews was often poor. This finding
was based on an assessment of the reporting of 300
systematic reviews published in a single month in 2014
and, in part, by comparison with data on the reporting
of 300 reviews published in the equivalent month in
2004 [2]. The research concluded that reporting had
improved since 2004, in large part due to developments
such as the publication of the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-
analyses) statement [3] as the relevant standard for the
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reporting of systematic reviews. However, it noted that
poor conduct and reporting was still frequent (indeed, it
was considered to be ‘suboptimal’ for many characteristics)
and strategies are needed to improve this if systematic
reviews are to offer genuine rather than just hypothetical
value to ‘patients, health care practitioners and policy-
makers’ [1]. This is important because the results of poorly-
conducted, reported or flawed systematic reviews include
‘misleading conclusions’, which can have major implications
for decision-making [1]. Consequently, Page et al. made a
series of highly appropriate and manageable recommenda-
tions to improve the conduct and reporting of systematic
reviews generally, and thus to re-establish the method as
trustworthy and robust as far as possible [1]. These in-
cluded using certain ‘writing tools’ to enforce reporting
guidelines; editorial application of guidelines; involve-
ment of relevant stakeholders from beyond the review
team; and assessing the reporting of bias within the sys-
tematic review itself [1].
The work also concluded that Cochrane reviews were
‘superior’ to ‘non-Cochrane’ reviews in terms of the ‘com-
pleteness’ of their reporting. This difference in relative
quality has been found in other work too, though with a
rather more critical assessment of the Cochrane reviews
themselves [4]. However, it is questionable whether ‘non-
Cochrane’ reviews represent a homogenous group: they
are published in many different journals and formats.
Some ‘non-Cochrane’ systematic reviews are commis-
sioned by policy-makers, or programmes related to policy-
makers, and as such already involve many safeguards
against the reporting of potentially ‘misleading conclu-
sions’. Health Technology Assessment (HTA) represents a
specific field in which the systematic review of clinical
effectiveness evidence plays a fundamental role in health-
care decision-making [5, 6]. These systematic reviews
therefore represent a distinct type of ‘non-Cochrane’
review. One such group of systematic reviews are those
conducted for the UK National Institute of Health Re-
search, (NIHR) HTA programme; the full versions of
these systematic reviews are published in that pro-
gramme’s own journal series, Health Technology
Assessment (Winchester) [7]. This series of ‘non-
Cochrane’ systematic reviews represents an interesting
and informative comparison with Cochrane reviews
given that, like Cochrane reviews, these reviews have
clear reporting standards and are not constrained by
word limits or the absence of online appendices unlike
many other ‘non-Cochrane’ reviews published in more
conventional peer-reviewed journals, an issue acknowl-
edged by Page et al. [1]. In fact, Page et al. do acknow-
ledge that the apparent bias in quality of reporting in
favour of Cochrane reviews might not always be bias in
the conduct or reporting of the reviews at all, but ra-
ther might be due to the restriction of word limits [1].
The aim of this research therefore is to compare the
reporting of systematic reviews published in the UK
Health Technology Assessment journal series with the
reporting of systematic reviews generally, and Cochrane
reviews specifically, from the years 2004 and 2014, as re-
ported by Page et al. [1]. A brief assessment will be made
of developments between 2004 and 2014 for UK HTA
systematic reviews, but the key comparison is across the
UK HTA, Cochrane and ‘non-Cochrane’ reviews from
2014 because this offers the best evidence on current
practice and standards. This comparison is important
because it seeks to underline not only how so-called
‘non-Cochrane reviews’ are not all the same, but that the
context in which systematic reviews are produced is a
key driver in standards of conduct and reporting. Fur-
ther, some of the recommendations for improved prac-
tice made by Page et al. are arguably already being met
by the staff and editorial processes involved in the pro-
duction of the Health Technology Assessment journal
systematic reviews, and so a comparison with these
systematic reviews might potentially offer further sup-
port for the authors’ proposals.
Methods
The data from the Cochrane and ‘non-Cochrane’ system-
atic review samples from a single month in each of 2004
and 2014 were published in the paper by Page et al. [1].
In order to generate the data for the proposed compari-
son between UK HTA systematic reviews and the
systematic reviews reported in Page et al., [1], a simple
search was performed in August 2016 to identify the
systematic reviews published in the Health Technology
Assessment monograph series from 2004 and 2014. This
involved a structured search of MEDLINE combining
title or abstract terms for ‘systematic review’ with the
Health Technology Assessment journal identifier (‘health
technology assessment winchester england.jn’), and the
application of date limits (2004 and 2014). The current
paper has included Health Technology Assessment sys-
tematic reviews from the whole of the designated years
(rather than just one month) in order to generate a suffi-
ciently sizeable sample from this single journal for com-
parison with the data published by Page et al. [1]. All of
the systematic reviews were published in English. The
searching and screening process was conducted by one
reviewer (CC) and checked by a second (EK).
Data extraction used a version of the form published by
Page et al. [1] with some modifications, e.g. the addition of
a ‘Not Applicable’ option. The form was piloted by the two
reviewers (CC, EK) on four Health Technology Assessment
journal systematic reviews to enhance consistency and
accuracy of extraction. Each reviewer then extracted half of
the Health Technology Assessment systematic reviews.
The data extracted included type of review, number of
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included studies, availability of protocols, details of search
strategies, inclusion criteria, critical appraisal tools, synthe-
sis methods etc.. Data were summarized as frequencies and
percentages for categorical items and as median and range
for continuous items. Results from the Health Technology
Assessment systematic reviews from 2004 and 2014 were
tabulated alongside the previously published results from
the Cochrane reviews and ‘non-Cochrane’ systematic
reviews from the same years from the paper by Page et al.
[1] These data were then compared and discussed.
Results
The MEDLINE search for Health Technology Assessment
journal systematic reviews found 462 unique citations.
Twenty-two were Health Technology Assessment publica-
tions with a systematic review of the clinical evidence from
2004 and 30 were equivalent publications from 2014. The
total number of Health Technology Assessment mono-
graphs to be extracted therefore was 52, but one mono-
graph contained two relevant reviews [8], so the total
number of reviews extracted was 53. A list of the included
reports is available in Additional file 1. The number of 30
UK HTA systematic reviews for 2014 compares reasonably
with the sample of 45 Cochrane reviews from 2014. The
Page et al. study also reported on 255 non-Cochrane re-
views from 2014 and 300 systematic reviews published in
2004 [1]. This latter sample, and the ‘non-Cochrane’ re-
views sample from 2014, might have included some of the
Health Technology Assessment journal systematic reviews,
but the detailed data are not available to confirm this or to
establish what proportion of the Health Technology
Assessment journal systematic reviews were included.
Disease areas
Fifty of the 53 systematic reviews covered seventeen
different disease areas (the remaining three publications
were reviews of methods [9–11]). The disease areas
covered by the Health Technology Assessment reviews
were principally neoplasms (16%), diseases of the circu-
latory systems (16%), and endocrine, nutritional or
metabolic diseases (14%). The proportions of Health
Technology Assessment systematic reviews covering
certain disease areas were mostly similar to those found
for systematic reviews generally in 2014. A full list is
provided in Table 1.
Topics and administrative information
In terms of the basic distribution of the reviews,
Cochrane reviews in 2014 exclusively covered thera-
peutic topics, while just over half of Health Technology
Assessment and other ‘non-Cochrane’ reviews did so (53
and 55% respectively): see Table 2. This was less than
2004, when the respective proportions were 70 and 71%.
More than half of the Cochrane reviews in 2014 evalu-
ated pharmacological interventions, compared with 20%
of HTA systematic reviews from the same year. The type
Table 1 Disease areas covered by included systematic reviews (the HTA data were collected for this study; the other data are from
Page et al. [1])
Disease area HTAs 2004 & 2014 Systematic reviews 2004 [1]a Systematic reviews 2014 [1]a
Neoplasms (i.e. cancers, carcinomas, tumours) 8 (16%) 22 (7%) 49 (16%)
Diseases of the circulatory system 8 (16%) 33 (11%) 34 (11%)
Endocrine, nutritional or metabolic disease 7 (14%) NR 23 (8%)
Mental and Behavioural 5 (10%) 40 (13%) 22 (7%)
Infections and parasitic diseases 3 (6%) 22 (7%) 41 (14%)
Diseases of the nervous system 3 (6%) NR NR
Musculoskeletal 3 (6%) NR 20 (7%)
Diseases of the eye and adnexa 2 (4%) NR NR
External causes of mortality and morbidity 2 (4%) NR NR
Genito-urinary 2 (4%) NR NR
Diseases of the digestive system 2 (4%) 20 (7%) 25 (8%)
Ear and mastoid process 1 (2%) NR NR
Pregnancy and birth 1 (2%) NR NR
Blood 1 (2%) NR NR
Skin and subcutaneous tissue 1 (2%) NR NR
Congenital malformations 1 (2%) NR NR
Total 50 (100%) 137b 214b
HTA Health Technology Assessment; aAs reported by Page et al. [1] bPage et al. did not report values less than 7% so not all 300 systematic reviews are included;
NR: Not reported
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Table 2 Basic distribution characteristics and administrative information of included systematic reviews (the HTA data were
collected for this study; all other data are from Page et al. [1], i.e. the data collected for 300 systematic reviews for a single month in
2004 and 2014)
Characteristic 2004 n = 300 [1] HTA 2004 n = 23 HTA 2014 n = 30 Cochrane 2014
n = 45 [1]
2014 n = 300 [1]
Number of authors: Median
and range a
4 (1- > 7) 4 (2–8) b 4 (1–9) b 4 (3–6) 5 (4–6)
Update of previous SR - (18%) 1 (4) 2 (7) 25 (56%) 31 (10%)
Type of SR
Therapeutic 213 (71%) 16 (70%) 16 (53%) 45 (100%) 164 (55%)
Diagnostics / prognostics 23 (8%) 5 (22%) 10 (34%) 0 33 (11%)
Epidemiology 38 (13%) 2 (8%) 1 (3%) 0 74 (25%)
Other (incl. methodological) 46 (15%) 0 3 (10%) 0 29 (10%)
Type of intervention
Pharmacological - (47%) 13 (57%) 6 (20%) 23 (51%) 76/164 (46%)
Non-pharmacological - (38%) 3 (13%) 13 (43%) 17 (38%) 75/164 (46%)
Both NR 1 (4%) 2 (7%) 5 (11%) 13/164 (8%)
Not applicable (e.g. diagnostic
test)
NR 6 (26%) 9 (30%) 0 0
Reporting guideline cited NR 5/23 (24%) 19/30 (63%)c 1 (2%) 87 (29%)
Cochrane methods used NR 1/23 (4%) 4/30 (13%) 45 (100%) 138 (46%)
Number of included studies 16 (1–170) [1–84] 0–200 9 (4–17) 15 (8–25)
Number of included participants
reported
1112 2 only (2905–3909) 5 only (201–34,082) 1113 (421–2751) 2072 (672–8033)
Empty review (no eligible studies) NR 0 2 (7%) 3 (7%) 4 (1%)
Meta-analysis performed - (54%) 11 (48%) 15 (50%) 32 (71%) 189 (63%)
Number of studies included in
largest meta-analysis
NR 4–17 (n = 11) 2–35 (n = 15) 6 (3–11) 9 (6–17)
Harms considered (excluding
empty / diagnostic reviews;
treatment reviews only)
- (75%) 15/16 (94%) 10/14 (71%) 41 (91%) 113/164 (69%)
Economics (i.e. costs) considered - (24%) 0d 0d 7 (16%) 23/172 (13%)
SR or Meta-analysis mentioned
in title / abstract
- (50%) 23 (100%) 30 (100%) 15 (33%) 254 (85%)
Review registered NR 0/23 (0%) 23/30 (77%) 0 (0%) 12 (4%)
Protocol available NR 4/23 (17%) 27/30 (90%) 44 (98%) 49 (16%)
Protocol mentioned but not
available
NR 7/23 (30%) 1/30 (3%) NR NR
Conflicts of Interests reported
Review authors NR 23 (100%) 30/30 (100%) 45 (100%) 260 (87%)
Included studies’ authors NR 6/23 (26%) 12/28 (43%) 13/42 (31%) 21/296 (7%)
Source of funding
Not for profit - (48%) 23 (100%) 30/30 (100%) 38 (84%) 142 (47%)
For profit - (2%) 0 0 0 (0%) 8 (3%)
Mixed - (6%) 0 0 0 (0%) 2 (1%)
No funding - (1%) 0 0 5 (11%) 39 (13%)
Not reported - (41%) 0 0 2 (4%) 109 (36%)
HTA Health Technology Assessment; aInterquartile range for non-Health Technology Assessment data; bIncluding information specialists, who are sometimes not
listed as an author, but appear in the Acknowledgements; cSome cite a combination of guidelines, e.g. PRISMA and York Centre for Reviews and Dissemination
(CRD) guidance; dEach clinical systematic review was accompanied by a separate cost-effectiveness systematic review and economic model; NR Nor reported
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of reviews conducted for the UK HTA programme was
also different in 2004 and 2014: by 2014 Health Tech-
nology Assessment reviews in particular were much
broader than Cochrane or other non-Cochrane reviews
in their remit, covering therapies, diagnostics, prognos-
tics and prevention, epidemiology and methodology.
One quarter (25%) of other non-Cochrane reviews
focused on epidemiology.
There are several similarities in the nature and report-
ing across the various systematic reviews. However, there
are some notable differences too, as detailed in Table 2.
These include the much larger range of included studies,
with higher maximum numbers of included studies in
the reviews and associated meta-analyses of the Health
Technology Assessment reviews; the failure of Health
Technology Assessment reviews to report the total num-
ber of participants involved in the studies included in a
review (these reviews tend to report the number of par-
ticipants across included studies as a range rather than a
single total); the registering and availability of systematic
review protocols; and a statement specifying that named
guidelines had been followed in the conduct of the
review. Reporting regarding protocols (an increase from
17 to 90%) and guidelines (an increase from 24 to 63%)
differed markedly in the Health Technology Assessment
sample between 2004 and 2014. However, it should also
be noted that the reporting of the Health Technology
Assessment systematic reviews compares favourably
with the Cochrane reviews in terms of this administra-
tive information– as well as information on conflicts of
interest and funding - and is consistently more complete
than the reporting of other so-called ‘non-Cochrane’
reviews. For example, for HTA, Cochrane and non-
Cochrane reviews respectively, the availability of proto-
cols was 90, 98 and 16%, and the reporting of authors’
conflicts of interests was 100, 100 and 87%.
Perhaps surprisingly there were relatively similar
numbers of ‘empty’ systematic reviews (reviews with-
out any included studies) across the different types of
reviews: for reviews from 2014, there were three empty
Cochrane reviews (7%); two empty Health Technology
Assessments (7%), and four empty non-Cochrane /
non-HTA reviews (1%). However, these figures are
much lower than is known for Cochrane reviews
generally [12]. Health Technology Assessment reviews
are commissioned and conducted within a particular
evidence-based and policy-making context, which per-
mits the consideration of study designs other than
RCTs or quasi-RCTs [12], so the presence of two
‘empty reviews’ in the 2014 sample is therefore unex-
pected. It is clear, however, that every effort was made
in these reviews to find useable evidence from any
comparative study design, but the only available data
were from trials with completely different groups in
each arm [13] or the complete absence of any relevant
comparative studies at all, of any design [14].
Inclusion criteria and search strategies
The 2014 HTA reviews were also consistently better at
reporting on these criteria than other non-Cochrane
reviews (see Table 3). Cochrane reviews were the best
reported in terms of explicitly reporting on the inclusion
of published and unpublished studies, but less explicit
than HTA reviews in terms of reporting language
criteria. Given the differing contexts in which the vari-
ous reviews were produced, and their differing scopes,
Cochrane reviews unsurprisingly included a much more
restricted evidence base (89% of reviews only included
randomized controlled trials [RCTs] or ‘quasi-RCTs’),
while the non-Cochrane reviews included a much
broader evidence base of study designs in order to
answer the questions addressed by the reviews (includ-
ing cohort studies for diagnostic reviews, for example).
More HTA reviews in 2014 than 2004 explicitly reported
whether the review included both published and unpub-
lished studies, and whether it included studies in English
only or other languages too.
The reporting of the database searches represented
one area where there was little difference between
2004 and 2014 in the HTA reviews: the reporting stan-
dards were extremely high in both years. In fact, the
HTA reviews were much better reported than other
non-Cochrane reviews and slightly superior also to
Cochrane reviews in this sample, for example, in inter-
rogating one or more trial registries.
Screening, extraction and risk of bias assessment
In terms of the conduct and reporting of the study selec-
tion, data extraction and critical appraisal processes, the
HTA reviews had some small differences between 2004
and 2014, and were consistently better-reported than the
other non-Cochrane reviews (see Table 4). Respectively
for data extraction and quality assessment, either two re-
viewers were reported to have completed the processes,
or one reviewer conducted the process, with all data be-
ing checked by a second reviewer, in 93 and 88% of 2014
Cochrane reviews, compared with 86 and 79% of HTA
reviews, and 65 and 52% of other ‘non-Cochrane’ re-
views. The Cochrane reviews more frequently conducted
these processes using two reviewers working independ-
ently (best practice), while standard practice in HTA re-
views was generally to have the extracted data and
critical appraisal judgments of one reviewer checked by
a second reviewer. Other non-Cochrane reviews did also
tend to favour two reviewers working independently
(55%), but were also less likely to report exactly what
was done (33% of reviews compared with 7% of HTA re-
views and 2% of Cochrane reviews).
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Inevitably, given the almost exclusive inclusion of RCTs
or similar, the vast majority of Cochrane reviews used the
Cochrane Risk of Bias tool to appraise included studies,
while the non-Cochrane reviews, which included a much
more diverse evidence base, used a broader range of tools.
It is noteworthy, however, that HTA reviews had ceased to
use the Jadad tool by 2014 (though other non-Cochrane
reviews did continue to use this), and that a third of HTA
reviews used critical appraisal criteria outlined by the York
CRD guidance on conducting systematic reviews [15],
Table 3 Eligibility criteria and searches (the HTA data were collected for this study; all other data are from Page et al. [1], i.e. the
data collected for 300 systematic reviews for a single month in 2004 and 2014)
Characteristic 2004 n = 300 [1] HTA 2004 n = 23 HTA 2014 n = 30 Cochrane 2014
n = 45 [1]
2014 n = 300 [1]
Type of included literature
Published and unpublisheda - (41%) 9/23 (39%) 19 (65%) 41 (91%) 116 (39%)
Published only - (23%) 0 1 (5%) 2 (4%) 80 (27%)
Not reported - (36%) 14/23 (61%) 10 (33%) 2 (4%) 103 (34%)
All languages - (37%) 11 (48%) 18 (60%) 37 (82%) 129 (43%)
English only - (16%) 9 (39%) 11 (37%) 1 (2%) 92 (31%)
Not reported - (45%) 3 (13%) 1 (3%) 6 (13%) 48 (16%)
Study design criteria specifiedb - (72%) 21/23 (93%) 30/30 (100%) 45 (100%) 237 (79%)
RCTs NR 15 (65%) 25 (83%) 44 (98%) 158 (53%)
Quasi-RCTs NR 3 (13%) 11 (37%) 14 (31%) 33 (11%)
Controlled NR 3 (13%) 12 (40%) 4 (9%) 30 (10%)
Cohort NR 1 (4%) 12 (40%) 0 (0%) 76 (25%)
Case-control NR 0 (0%) 4 (13%) 0 (0%) 49 (16%)
Other NR 5 (22%) 4 (13%) 1 (2%) 56 (19%)
Unclear NR 2 (9%) 2 (6%) 0 (0%) 36 (12%)
Only RCTs / Quasi-RCTs NR 9 (39%) 8 (27%) 40 (89%) 107 (36%)
Number of databases median
(range)
3 10 (4–15) 9 (2–13) 5 (4–6) 4 (3–5)
Start / end dates of all
databases given
- (69%) 20/23 (87%) 28 (93%) 41 (91%) 196 (65%)
Only some start / end
dates given
- (16%) 1/23 (4%) 2 (7%) 4 (9%) 88 (29%)
Full search given of ≥ 1
database
- (42%) 21/23 (91%) 30 (100%) 44 (98%) 134 (45%)
Other sources searched
One or more trial registriesa NR 12 (52%) 21 (70%) 28 (62%) 58 (19%)
Number of other source
types searched
NR 3 (1–6) 3 (1–6) 2 (1–3) 1 (1–2)
Grey literature NR 8 (35%) 15 (50%) 9 (20%) 21 (7%)
Reference lists NR 21 (91%) 26 (87%) 38 (84%) 243 (81%)
Conference abstracts NR 7 (30%) 10 (33%) 11 (24%) 47 (16%)
Experts NR 7 (30%) 16 (53%) 23 (51%) 54 (18%)
Handsearching particular
journals
NR 5 (22%) 3 (10%) 6 (13%) 25 (8%)
Manufacturers NR 14 (61%) 4 (13%) 8 (18%) 11 (4%)
Regulators NR 3 (13%) 0 (0%) 0 (0%) 2 (1%)
Citation tracking NR 2 (9%) 2 (7%) 8 (18%) 35 (12%)
HTA Health Technology Assessment; aNote: there are some inconsistencies in the data because a search for ‘unpublished’ data might not be noted explicitly in the
Methods of a Health Technology Assessment systematic review, but trial registers and grey literature are searched and often included and have much higher
percentages bSome of the figures do not add-up to 100% because, for example in study designs, a systematic review might include more than one design; NR
Not reported
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which essentially had formed the basis of the UK HTA
systematic review programme for many years. This was
the HTA equivalent of Cochrane using the Cochrane risk
of bias tool.
Included studies, outcomes, analyses and findings
There were clear differences in the proportions of HTA
reviews reporting full details of included and excluded
studies between 2004 and 2014, and these reviews were
superior to Cochrane and other non-Cochrane reviews in
the reporting of these details (see Table 5). A substantially
higher proportion of HTA reviews from 2014 also in-
cluded grey literature (30%) than either Cochrane (18%)
or non-Cochrane reviews (9%): this is likely due in part to
the provision of unpublished data by companies or
sponsors whose technologies were being assessed within
the HTA reviews, but also because, as indicated in Table 3
above, more HTA reviews (50% compared with 20% of
Cochrane reviews and 7% of non-Cochrane reviews) made
efforts to search for this type of data.
Only a very small proportion of HTA reviews reported
the total number of participants from the included stud-
ies, contrasting sharply with the reporting of this charac-
teristic in Cochrane and other non-Cochrane reviews.
This is due in large part to a different convention apply-
ing in Health Technology Assessment reviews, i.e. the
reporting of the range of numbers of participants from
the included studies, e.g. ‘the five trials included between
50 and 150 patients’. Cochrane reviews were more likely
to specify a primary outcome than Health Technology
Table 4 Screening, extraction and risk of bias assessment in the included systematic reviews (the HTA data were collected for this
study; all other data are from Page et al. [1], i.e. the data collected for 300 systematic reviews for a single month in 2004 and 2014)
Characteristic 2004 n = 300 [1] HTA 2004 n = 23 HTA 2014 n = 30 Cochrane 2014
n = 45 [1]
2014 n = 300 [1]
Screening
By at least two authors NR 14 (61%) 22 (73%) 44 (98%) 200 (67%)
By one author, with a sample
screened by a second
NR 2 (9%) 3 (10%) 1 (2%) 7 (2%)
By one author only NR 2 (9%) 1 (3%) 0 (0%) 6 (2%)
Not reported / Unclear NR 5 (22%) 4 (13%) 0 (0%) 87 (29%)
Empty review (no included /
eligible studies)
NR 0/23 (0%) 2/30 (7%) 3/45 (7%) 4/300 (1%)
Extraction NR n = 23 n = 28 n = 42 n = 296
By at least two authors NR 4 (17%) 5 (18%) 41 (98%) 163 (55%)
By one author, with data
verified by a second
NR 14 (61%) 19 (68%) 0 (0%) 29 (10%)
By one author only NR 1 (4%) 2 (7%) 0 (0%) 7 (2%)
Not reported / Unclear NR 4 (17%) 2 (7%) 1 (2%) 97 (33%)
Quality assessment - (67%) 23 (100%) 28 (100%) 42 (100%) 206 (70%)
By at least two authors NR 5 (22%) 10 (36%) 37 (88%) 121/206 (59%)
By one author, with data
verified by a second
NR 11 (48%) 12 (43%) 0 (0%) 6/206 (3%)
By one author only NR 1 (4%) 0 (0%) 0 (0%) 3/206 (1%)
Not reported NR 6 (26%) 6 (21%) 5 (12%) 76/206 (37%)
Risk of bias / quality
assessment tool
Cochrane (or modification) NR 2 (9%) 12 (43%) 37 (88%) 77 (37%)
Jadad NR 4 (17%) 0 (0%) 0(0%) 33 (11%)
Newcastle-Ottowa NR 0 0 (0%) 1 (2%) 17 (8%)
QUADAS, QUADAS-2 NR 1 (4%) 5 (18%) 0 (0%) 8 (4%)
Own NR 2 (9%) 3 (11%) 2 (5%) 38 (18%)
Other NR 14 (61%)a 9 (32%)a 3 (7%) 53 (26%)
Not reported NR 1 (4%) 1 (4%) 0 (0%) 6 (3%)
Selective reportingb NR 0 10/28 (36%) 36/42 (86%) 70 (24%)
HTA Health Technology Assessment aEspecially CRD criteria, which are arguably as appropriate to UK HTA as the Cochrane risk of bias tool is to Cochrane reviews.
bNot always applicable, e.g. diagnostics: it is not a field in the QUADAS tool; NR Not reported
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Table 5 Review flow reporting, included studies, outcomes and analyses in the included systematic reviews (the HTA data were
collected for this study; all other data are from Page et al. [1], i.e. the data collected for 300 systematic reviews for a single month in
2004 and 2014)
Characteristic 2004 n = 300 [1] HTA 2004 n = 23 HTA 2014 n = 30 Cochrane 2014
n = 45 [1]
2014 n = 300 [1]
Review flow reporting
PRISMA-like flow diagram (and text) - (7%) 13 (57%) 29 (97%) 23 (51%) 206 (69%)
Text/tables or flowchart only - (35%) 8 (35%) 1 (3%) 5 (11%) 20 (7%)
Partially reported - (33%) 0 0 (0%) 7 (16%) 38 (13%)
Not reported - (31%) 2 (9%) 0 (0%) 10 (22%) 36 (12%)
Reasons for exclusion of full text
articles reported
PRISMA-like flow diagram and
text/tables
- (48%) 15 (65%) 27 (91%) 41 (91%) 211 (70%)
Partial (only reasons for some
exclusions provided)
- (40%) 5 (22%) 1 (3%) 4 (9%) 28 (9%)
Not reported - (17%) 3 (13%) 2 (7%) 0 (0%) 61 (20%)
Grey literature included in review
Yes NR 18 (78%) 9 (30%)* 8 (18%) 26 (9%)
Total number of included
participants reported
In main text NR 2/23 (9%) 4/28 (14%) 39/42 (93%) 194/296 (66%)
In abstract NR 1/23 (4%) 4/28 (14%) 37/42 (88%) 147/296 (50%)
At least one outcome reported
in Methods
NR 21/23 (96%) 30 (100%) 45 (100%) 234 (78%)
A specified primary outcome - (51%) 6 (26%) 16 (53%) 43(96%) 136/288 (47%)
Meta-analysis
No (includes empty reviews or reviews
with a statement that studies could
not be combined)
NR 12 (52%) 15 (50%) 13 (29%) 111 (37%)
Yes NR 11 (47%) 15 (50%) 32 (71%) 189 (63%)
Statistical heterogeneity investigated
Quantitative - (91%) 9/11 (82%) 13 (87%) 32/32 (100%) 175/189 (93%)
Not reported NR 2/11 (18%) 1/15 (7%) 0 (0%) 12 (7%)
Risk of bias incorporated in
meta-analysis
NR 0/23 (0%) 1/15 (7%) 4/32 (13%) 31/189 (16%)
Publication bias
Formally assessed (Funnel plot etc.) NR 0/23 (0%) 6/30 (20%) 7 (16%) 93 (31%)
Not assessed, but planned if sufficient
studies
NR 1/23 (4%) 2/30 (7%) 28 (62%) 37 (12%)
Possibility discussed/considered in
results, discussion etc.
- (31%) 0/23 (0%) 6/30 (20%) 29 (64%) 141 (47%)
GRADE assessment reported NR 0 (0%) 0 (0%) 27 (60%) 32 (11%)
Limitations reported in Discussion/
Conclusion
At study level and review level NR 11 (49%) 19 (63%) 32 (71%) 173 (58%)
Study-level only NR 10 (44%) 6 (20%) 10 (22%) 67 (22%)
Review-level only NR 0 3 (10%) 0 (0%) 27 (9%)
Not reported NR 2 (7%) 2 (7%)
Risk of bias / quality assessment
reported
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Assessment or other non-Cochrane reviews, and also more
likely to perform a meta-analysis, although this is no
surprise given the more restrictive parameters of Cochrane
reviews, which are more likely to produce potentially
homogenous data sets amenable to such analysis. This
sample of HTA reviews was particularly poor in compari-
son with both Cochrane and other non-Cochrane reviews
in addressing or even acknowledging publication bias. The
2014 Health Technology Assessment reviews also did not
apply the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) process at all [16]
and were less likely than Cochrane to mention the findings
of the quality assessment process in the abstract. This latter
issue might be due to two reasons: first, the brief abstracts
for the HTA reviews do not include only the findings from
the systematic review of the clinical evidence, but must
also include the findings of the cost-effectiveness review
and analyses that often accompany them. Second, Health
Technology Assessment reviews also include a so-called
‘Scientific summary’ (2014) or ‘Executive summary’ (2004),
a type of longer, structured abstract, in addition to the brief
abstract. In the 2014 sample, only 8/14 (57%) of the
therapeutic reviews with included studies mentioned
risk of bias in the abstract but 11/14 (79%) included
comments on quality assessment of the included stud-
ies in the Scientific summary.
Discussion
The principal findings of this assessment are twofold. First,
and previously undocumented, the standard of reporting is
often comparable between UK Health Technology Assess-
ment systematic reviews and Cochrane reviews, and the
reporting in both appears to be more complete than other
non-Cochrane reviews. Second, there were clear improve-
ments in the conduct and reporting of Health Technology
Assessment systematic reviews between 2004 and 2014,
consistent with the findings of Page et al. regarding other
‘non-Cochrane’ and Cochrane systematic reviews [1].
Based on these data, the reporting of the Health Technol-
ogy Assessment journal systematic reviews was comparable
to Cochrane reviews and ‘superior’ to other non-Cochrane,
across many characteristics: identification as a systematic
review; registering of reviews and availability of protocols;
conflicts of interest; reporting of the type of literature
included; details of the database search strategies; searching
of trial registries and grey literature; the use of PRISMA
flow diagrams; the provision of details of any excluded
studies; and the reporting of limitations at the level of the
review and of the included studies. All of these elements
have particular implications for informing decision-
making, especially the importance of sourcing unpub-
lished data [17, 18] and clarifying uncertainties within
the evidence-base and review itself. This was all achieved
despite the much broader scope of the Health Technology
Assessment reviews compared with Cochrane reviews:
Health Technology Assessment reviews covered a range of
topics and included a diversity of study designs, while the
Cochrane reviews exclusively covered therapeutic topics,
mostly evaluating pharmacological interventions based
almost exclusively on RCT or quasi-RCT evidence (100%
of reviews compared with 53% of HTA reviews). Some of
the other differences between Health Technology Assess-
ment and Cochrane reviews, such as one reviewer in the
former extracting and appraising studies, and a second
checking those data and judgements, compared with
double-extraction in Cochrane reviews, might also be
explained by the relative scale of the task being faced by
Health Technology Assessment reviewers compared with
Cochrane reviewers. For example, the 2014 Health Tech-
nology Assessment reviews included reports with up to
200 studies, compared with 17 at the highest end of the
interquartile range (IQR) in Cochrane reviews. Given the
much larger number of included studies, the diverse ques-
tions and study designs, and the time constraints that
govern HTA reviews (UK HTA reviews typically must be
completed six to nine months after protocol approval)
[19], unlike Cochrane reviews, some best practice ‘short-
cut’ approaches are understandable. As a result, conduct
and reporting is arguably much more straightforward
within the narrower bounds of Cochrane systematic
reviews, than in the broader, more diverse context in
which certain non-Cochrane reviews are produced, espe-
cially Health Technology Assessment reviews.
At first glance, Health Technology Assessment reviews
have weaker reporting than Cochrane reviews across
several particular characteristics: total number of partici-
pants across the included studies; details of risk of bias
assessments being reported in abstracts; specification of a
primary outcome; a consideration of economics; the appli-
cation of GRADE to ‘weigh’ evidence for the purposes of
Table 5 Review flow reporting, included studies, outcomes and analyses in the included systematic reviews (the HTA data were
collected for this study; all other data are from Page et al. [1], i.e. the data collected for 300 systematic reviews for a single month in
2004 and 2014) (Continued)
Characteristic 2004 n = 300 [1] HTA 2004 n = 23 HTA 2014 n = 30 Cochrane 2014
n = 45 [1]
2014 n = 300 [1]
In Abstract (Therapeutic reviews only) NR 7/16 (44%) [63%‡] 8/14a (57%) [79%b] 42 (93%) 99/164 (60%)
HTA Health Technology Assessment, PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses, GRADE Grading of Recommendations Assessment,
Development and Evaluation (short GRADE); aExcluding two empty reviews bPercentage that include this in Executive or Scientific Summary
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recommendations [16]; and publication bias. Some of these
‘deficiencies’ are easily explained and arguably should not
be considered an issue. For example, Health Technology
Assessment systematic reviews tend to report the range of
participants across the included studies rather than a total,
conduct economic evaluations as a distinct but related
piece of work, and include risk of bias assessments in the
larger Executive Summary rather than the brief Abstract,
where the results of the accompanying cost-effectiveness
analysis must also be reported. Health Technology Assess-
ment systematic reviews are also not expected to develop
recommendations based on the quality of the evidence – it
is simply not a function of this type of systematic review–
the responsibility for making recommendations lies with
other groups in the HTA process [7, 19]. As a result, not
one of the Health Technology Assessment reviews in 2014
reported using GRADE [16]. The one definite issue of poor
conduct and reporting, however, concerns publication bias.
This is simply almost never taken into account in Health
Technology Assessment systematic reviews, but should be,
without question.
The conduct and reporting of UK Health Technology
Assessment journal reviews is therefore of the same stand-
ard as Cochrane reviews and generally more complete, and
better, than many other reviews. Consequently, they should
arguably not be ‘lumped together’ with other ‘non-
Cochrane’ reviews, but considered as the equivalent of that
perceived Cochrane ‘gold standard’. This raises the question
why this set of reviews is so well-conducted and reported.
The reason lies in the context in which they are produced:
UK Health Technology Assessment reviews are commis-
sioned by bodies associated with the UK Department of
Health (National Institute of Health and Care Excellence
[NICE] and the National Institute of Health Research
[NIHR]) and with a specific policy-making and decision-
making purpose and audience in mind [7]. While all
reviews theoretically exist to support evidence-based prac-
tice [20, 21], not all reviews are produced within a process
that exists to do so [19] and such a relationship is needed if
research is to stand a chance of being influential [22]. So,
while many reviews might be produced with the potential
to influence practice, few are actually commissioned as an
integral part of a process which is able to develop policy
and inform practice [19]. Rather, as Page et al. have pointed
out, it is to be suspected that many reviews are undertaken,
and published, with rather less lofty aims in mind, such as a
need to publish in order to secure promotions or funding
for the authors [1]. There is also a concern that these
authors do not have the skills to conduct and report
systematic reviews as well as they should [1]. By contrast,
the UK Health Technology Assessment journal reviews
covered here often form part of a wider policy-making
process – including taking into account cost-effectiveness
of health technologies– with the aim of answering specific,
policy-led questions, often about clinical decision-making
and resource allocation, which can directly influence guid-
ance and practice [7, 23]. The fact that Health Technology
Assessment reviews are produced within such a context of
evidence-based medicine, with the genuine potential to in-
fluence practice and be useful, means that the processes
have to be rigorous, transparent and of the highest quality:
‘bias’ in the review needs to be minimized; the possibility of
‘misleading conclusions’, attributed by Page et al. to a
sizeable number of non-Cochrane reviews, cannot be per-
mitted in Health Technology Assessment reviews because
there is too much riding on their findings [21, 23]. Given
these implications, the HTA process has long included
multiple specialist staff, as well as stakeholders outside of
the review team who interrogate the work, and a rigorous
editorial process for the Health Technology Assessment
journal (which includes the requirement of a completed
and checked PRISMA checklist). Such collaborations be-
tween funders, journals and academic institutions are all
recommended by Page et al. as strategies to improve the
conduct and reporting of systematic reviews generally [1].
This is an important consideration given that more
than 8000 systematic reviews are published each year
and, based on the sample of ‘non-Cochrane’ reviews
analyzed by Page et al., a sizeable proportion are likely
to be of ‘questionable quality’ [1].
Finally, there were apparent differences in conduct and
reporting of systematic reviews published by the UK HTA
programme, like all other reviews, between 2004 and 2014
across most domains, with the exception of the conduct
and description of the searches for the reviews, which were
of a very high standard in 2004 also. Overall, however,
these differences are most likely the result of the publica-
tion and general acceptance of the PRISMA statement
(Preferred Reporting Items for Systematic Reviews and
Meta-analyses) as the relevant standard for the reporting
of systematic reviews [3]. The 2009 PRISMA statement has
doubtless led to improved reporting across all domains,
but in this sample it unquestionably led to the following:
higher numbers of Health Technology Assessment teams
registering their review (70% of HTA reviews in 2014 com-
pared with 0% in 2004) and making protocols available
(90% compared with 17%); more complete reporting of
limitations affecting the review itself, rather than the
reporting of the limitations of included studies only (73%
of HTA reviews in 2014 compared with 49% in 2004); and
more complete reporting of decision-making regarding the
inclusion (97% of HTA reviews in 2014 compared with
57% in 2004) and exclusion (91 and 65% respectively) of
studies. Before 2009 the QUORUM (Quality of Report-
ing of Meta-analyses) statement existed to outline how
inclusion and exclusion should be reported, but this
was not applied in Health Technology Assessment
journal reviews nearly as rigorously as the PRISMA
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statement and its related checklist [24]. It is also clear
that conduct and reporting might have benefited from
a greater standardization both of guidelines for system-
atic reviews and of the tools for the critical appraisal of
included studies. Higher proportions of Health Technology
Assessment reviews in 2014 were likely to report having
followed guidelines in the conduct and reporting of the
review than those in 2004 (63% did so compared with 24%
in 2004) and, given the context in which they were pro-
duced, were as likely to cite the University of York Centre
for Reviews and Dissemination (CRD) guidance [15] as the
PRISMA statement [3]. The variety of available critical
appraisal tools used in 2004 had been replaced by a smaller,
more standardized set of tools by 2014, i.e. usage of the
Cochrane Risk of Bias tool [25] increased from 9% in 2004
to 43% in 2014, and the use of ‘other’ tools ‘decreased’ from
61% in 2004 to 32% in 2014 (the vast majority of these
‘other’ tools in 2014 consisted of the application of CRD
criteria for RCTs [15], which is ‘standard’ for Health
Technology Assessment reviews). By 2014, a version of the
QUADAS tool was being used for all of the HTA diagnostic
reviews and the Jadad score had been dropped com-
pletely (from 17% of HTA reviews in 2004 to 0% in
2014), despite continuing to be used in 11% of other
‘non-Cochrane’ reviews.
The limitations of this work need to be acknowledged:
this study only looked at a sample of HTA reviews from
two years, in order to offer a direct comparison with the
data presented by Page et al. [1], so results might be a
little different if other years were selected. This work
also only considered those characteristics previously
examined by Page et al. [1]; different characteristics
might have generated some different findings. Also, the
data in Page et al. [1] were not re-checked, but taken as
reported. Finally, some data are not straightforward (e.g.
a search for ‘unpublished’ data might not be noted expli-
citly in the Methods of a Health Technology Assessment
systematic review, but trial registers and grey literature
are searched and often included and have much higher
percentages), and so there might be some inconsistency
in data interpretation across this study and the study by
Page et al. [1] It should also be noted that this paper is
not making generalizations about systematic reviews as a
whole or all HTA systematic reviews.
Conclusion
The aim of this research was to compare the reporting of
systematic reviews published in the UK Health Technology
Assessment journal series with the reporting of systematic
reviews generally, and Cochrane reviews specifically. It
found that UK Health Technology Assessment systematic
reviews present standards of conduct and reporting equiva-
lent to so-called ‘gold standard’ Cochrane reviews and
superior to systematic reviews more generally. It therefore
makes sense to view any systematic review produced
within a genuine policy-context, and not just those from
the UK Health Technology Assessment journal, as being
on a par with Cochrane reviews and representing some-
thing quite different from other ‘non-Cochrane’ reviews.
Indeed, knowing the purpose behind the production of a
review – who commissioned the work, who funded the
work, why the work was being undertaken – might be an
obvious means by which users of reviews can ‘rate’ a
systematic review’s likely reliability and rigour, [21] along-
side assessments using the AMSTAR (Assessing the Meth-
odological Quality of Systematic Reviews) or ROBIS tools
[26, 27]. This is because reviews produced within a genuine
policy-making context will have enjoyed resources and
been through processes, given the implications of getting
things wrong, that apply to few other reviews. This is not
to say that other ‘non-Cochrane’ reviews produced outside
of this context cannot adhere to high standards of conduct
and reporting, of course they can; only that, based on the
evidence as presented here, in the hierarchy of systematic
reviews, UK Health Technology Assessment reviews de-
serve to be categorized as ‘gold standard’ alongside the
more universally known Cochrane library of reviews. This
is because the purpose behind these reviews resembles
most closely the purpose originally intended for systematic
reviews [20, 28]: to inform evidence-based medicine.
Further, as pieces of research, given the context in which
they are produced, they are more likely to be useful than
many other reviews, in the sense that their findings almost
certainly will be used, and all such research should be
capable of being used [29, 30]. Again, they satisfy many of
the requirements for genuinely useful research because
they form part of an explicit policy-driven process in which
time and money is expended with the specific aim of
telling practitioners what to do and what not do.
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